William Lis - 24 Sep 2021 Form 3 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Role
Chief Executive Officer, Director
Signature
By: /s/ Jeet Mahal, as Attorney-in-Fact
Issuer symbol
JSPR
Transactions as of
24 Sep 2021
Net transactions value
$0
Form type
3
Filing time
01 Oct 2021, 16:08:58 UTC
Next filing
14 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JSPR Stock Option (right to buy) 24 Sep 2021 Common Stock 730,850 $0.7100 Direct F1
holding JSPR Stock Option (right to buy) 24 Sep 2021 Common Stock 229,095 $0.7100 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the original number of shares subject to the option were vested as of June 1, 2020, the date of grant; 5% of the original number of shares subject to the option vested on June 21, 2020 and monthly thereafter through and including November 21, 2020; and 1.66% of the original number of shares subject to the option vested on December 21, 2020 and have vested and shall vest monthly thereafter through and including November 21, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2 1/18th of the original number of shares subject to the option vested on September 3, 2020, and 1/18th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney